EnGen Bio, founded as an early-stage biotechnology company, is dedicated to pioneering a universal flu vaccine. Their core mission is to revolutionize influenza prevention and treatment by targeting a novel epitope on the flu virus’s M1 matrix protein, aiming to elicit long-lasting and broadly neutralizing antibody responses in both humans and animals. This innovative approach sets them apart from conventional hemagglutinin or whole-virus-based vaccines, positioning EnGen Bio at the forefront of influenza research and prevention.
EnGen Bio has garnered significant attention and support from notable institutions such as the National Institutes of Health, Department of Defense, Department of Agriculture, and the Bill and Melinda Gates Foundation. These affiliations underscore the importance and potential impact of their work. The company's groundbreaking research has the potential to transform global health by providing a more effective and enduring solution to influenza, thereby reducing the disease's burden worldwide.
